Pre-surgical oncolytic virotherapy improves breast cancer outcomes

Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, contr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullins-Dansereau, Victor, Petrazzo, Grégory, Geoffroy, Karen, Béland, Delphine, Bourgeois-Daigneault, Marie-Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791421/
https://www.ncbi.nlm.nih.gov/pubmed/31646102
http://dx.doi.org/10.1080/2162402X.2019.1655363
_version_ 1783458978271854592
author Mullins-Dansereau, Victor
Petrazzo, Grégory
Geoffroy, Karen
Béland, Delphine
Bourgeois-Daigneault, Marie-Claude
author_facet Mullins-Dansereau, Victor
Petrazzo, Grégory
Geoffroy, Karen
Béland, Delphine
Bourgeois-Daigneault, Marie-Claude
author_sort Mullins-Dansereau, Victor
collection PubMed
description Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs).
format Online
Article
Text
id pubmed-6791421
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-67914212019-10-23 Pre-surgical oncolytic virotherapy improves breast cancer outcomes Mullins-Dansereau, Victor Petrazzo, Grégory Geoffroy, Karen Béland, Delphine Bourgeois-Daigneault, Marie-Claude Oncoimmunology Author's View Oncolytic viruses (OVs) are a novel class of cancer biotherapeutics with the ability to kill cancers and trigger anti-tumor immunity. Using murine models of cancer in pre-clinical proof-of-concept studies, we found that neoadjuvant OV administration before surgery efficiently prevents relapse, controls metastases and sensitizes tumors to immune checkpoint inhibitors (ICIs). Taylor & Francis 2019-08-19 /pmc/articles/PMC6791421/ /pubmed/31646102 http://dx.doi.org/10.1080/2162402X.2019.1655363 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's View
Mullins-Dansereau, Victor
Petrazzo, Grégory
Geoffroy, Karen
Béland, Delphine
Bourgeois-Daigneault, Marie-Claude
Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title_full Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title_fullStr Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title_full_unstemmed Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title_short Pre-surgical oncolytic virotherapy improves breast cancer outcomes
title_sort pre-surgical oncolytic virotherapy improves breast cancer outcomes
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791421/
https://www.ncbi.nlm.nih.gov/pubmed/31646102
http://dx.doi.org/10.1080/2162402X.2019.1655363
work_keys_str_mv AT mullinsdansereauvictor presurgicaloncolyticvirotherapyimprovesbreastcanceroutcomes
AT petrazzogregory presurgicaloncolyticvirotherapyimprovesbreastcanceroutcomes
AT geoffroykaren presurgicaloncolyticvirotherapyimprovesbreastcanceroutcomes
AT belanddelphine presurgicaloncolyticvirotherapyimprovesbreastcanceroutcomes
AT bourgeoisdaigneaultmarieclaude presurgicaloncolyticvirotherapyimprovesbreastcanceroutcomes

Ejemplares similares